In compliance with the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 as amended and pursuant to the Company's "Code of Conduct for Regulating & Reporting of Trading by Insiders and for Fair Disclosure", the 'Trading Window' for dealing in the securities of the Company will remain closed for Directors, Designated Employees and Connected Persons from January 1, 2023 till forty eight hours after the declaration of unaudited Financial Results of the Company for the Third quarter of the FY 2022-23.
The date for declaration of the financial results for the Third quarter of the FY 2022-23 shall be announced in due course.
Kindly dissipate the information on Exchange website.
Regards
For Kopran Limited
SODHANI SUNIL RADHEYSHYAM
Digitally signed by SODHANI SUNIL RADHEYSHYAM Date: 2022.12.27 16:03:00 +05'30'
Sunil Sodhani
Company Secretary & Compliance Officer
Membership No. FCS 3897
KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111
Kopran Ltd. published this content on 27 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2022 11:19:37 UTC.
Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.
KOPRAN LIMITED 
